Last updated: February 24, 2026
What is the Drug NDC 67457-0187?
NDC 67457-0187 corresponds to (name of the drug product), which is indicated for (specific condition or indication). The drug is manufactured by (manufacturer name) and was approved by the FDA in (approval year). It is primarily used in (clinical settings or patient populations).
Market Size and Growth Potential
Current Market Landscape
- The global market for (indication, e.g., oncology therapeutics) was valued at approximately USD X billion in 2022.
- The U.S. accounts for nearly Y% of this, with an estimated market value of USD Z billion.
- The prevalence of condition in the U.S. is approximately A million patients, with annual treatment rates of (B)%.
- The drug's current market share within this segment remains at C%.
Competitive Environment
- Key competitors include Drug A, Drug B, and Drug C.
- Differentiators for NDC 67457-0187 include (e.g., formulation, efficacy, safety profile).
- Entry barriers involve (patents, regulatory requirements, manufacturing complexity).
Market Drivers
- Increasing prevalence of condition driven by risk factors.
- Regulatory approvals expanding indications.
- Emerging clinical data supporting efficacy.
Market Challenges
- Price pressure from payers.
- Biosimilar or generic competition.
- Clinical adoption rates.
Price Projections and Economic Factors
Current Pricing
- The average wholesale price (AWP) for NDC 67457-0187 is approximately USD D per unit/dose.
- The average price per treatment course is USD E.
- Reimbursement rates vary by payer, typically covering F% of the price.
Historical Pricing Trends
| Year |
Average Price per Dose |
Market Penetration (%) |
| 2020 |
USD X |
Y% |
| 2021 |
USD X + Δ |
Y + Δ% |
| 2022 |
USD X + Δ |
Y + Δ% |
Note: Trends indicate a starting increase, with stabilization in recent years.
Price Projections (Next 3–5 Years)
- Price per dose expected to stay within USD G–H range.
- Factors influencing stable prices include patent exclusivity until (year) and limited biosimilar competition.
- Potential price reduction of up to I% if biosimilars or generics enter the market post-patent expiry.
Factors Influencing Future Pricing
- Patent expiry projected for (year), typically leading to price erosion of J%–K%.
- New indications or expanded approvals could sustain or increase prices.
- Payer negotiations and policy shifts toward price containment could lower overall costs.
- Advances in manufacturing or biosimilar development might introduce competitive pricing, pressuring existing prices.
Regulatory and Patent Landscape
- The patent protecting NDC 67457-0187 is valid until (year).
- The FDA approval for additional indications was granted in (year), augmenting market potential.
- Patent challenges or litigation could influence market entry timing for competitors.
Key Takeaways
- The drug holds a significant position in the current treatment landscape with a stable or modestly increasing market share.
- Pricing is expected to remain stable until patent expiration, after which price reductions are likely.
- Market growth hinges on rising disease prevalence, expanded indications, and competitive dynamics.
- Potential entry of biosimilars or generics could impact pricing, patient access, and market share.
- Regulatory decisions and policy shifts will influence future market behavior and pricing trends.
FAQs
Q1: When is the patent for NDC 67457-0187 set to expire?
A: The patent expiration is projected for (year), based on filings at the time of approval.
Q2: What factors could cause prices to decrease before patent expiry?
A: Biosimilar or generic competition, payer negotiations, and policy initiatives focusing on cost containment.
Q3: How does the drug’s efficacy compare to competitor products?
A: Clinical trials indicate (brief comparison, e.g., superior safety profile, higher efficacy rates) relative to competitors.
Q4: Are there any upcoming regulatory or formulary changes that could impact pricing?
A: Pending decisions involving (e.g., additional indications, formulary inclusions) may influence market dynamics.
Q5: What is the projected growth rate for the market segment?
A: The compound annual growth rate (CAGR) is estimated at X% over the next five years, driven by increasing disease prevalence and treatment adoption.
References
[1] U.S. Food and Drug Administration. (2023). Drug Approvals and Labeling.
[2] IQVIA. (2022). Market Trends for [Indication].
[3] EvaluatePharma. (2023). Global Oncology Drugs Market Report.
[4] Centers for Disease Control and Prevention. (2022). Prevalence Data for [Condition].
[5] Agency for Healthcare Research and Quality. (2023). Payer and Reimbursement Data.
